BRONXIAL ASTMA
Keywords:
Bronchial Asthma, bronxial yo‘llar, surunkali yallig‘lanish, bronxospazm, epizodik nafas qisishi, shamollash, yo‘tal, genetik omillar, allergenlar, infektsiyalar, T-hujayralar, eozinofillar, mast hujayralar, immun tizim, spirometriya, PEFR monitoringi, IgE, allergen testlari, inhalyatsion kortikosteroidlar, bronxodilatorlar, leukotrien retseptor antagonistlari, biotexnologik preparatlar, astma fenotiplari, individual davolash strategiyalari, kasallik fenotipi, profilaktika, hayot sifati.Abstract
Ushbu maqolada Bronchial Asthma kasalligining etiologiyasi, patogenezi, klinik kechishi, diagnostikasi va davolash tamoyillari ilmiy asosda yoritilgan. Bronxial astma — bu surunkali yallig‘lanish bilan bog‘liq respirator kasallik bo‘lib, bronxial yo‘llarning hiperreaktivligi, bronxospazm va episodik respirator simptomlar (shamollash, yo‘tal, nafas qisishi) bilan xarakterlanadi. Kasallikning rivojlanishida genetik omillar, atrof-muhitdagi allergenlar, infektsiyalar va immun tizimning nosoz reaksiyalari asosiy rol o‘ynaydi.
Maqolada astmaning molekulyar va immunologik mexanizmlari tahlil qilingan. T-hujayralar, eozinofillar va mast hujayralar yallig‘lanish jarayonida asosiy rol o‘ynaydi, bu esa bronxial yo‘llarda shish, mukus sekretsiyasi va bronxospazm rivojlanishiga olib keladi. Klinik jihatdan kasallik o‘zgaruvchan va epizodik simptomlar bilan namoyon bo‘lib, o‘tkir astma krizlari bemorlar hayotiga xavf solishi mumkin.
Diagnostika jarayonida spirometriya, bronxial provokatsiya testlari, PEFR monitoringi va laborator tekshiruvlar (IgE darajasi, allergen testlari) qo‘llaniladi. Shuningdek, astma fenotiplari va allergik profil asosida individual davolash strategiyalari ishlab chiqiladi.
Davolash odatda surunkali yallig‘lanishni kamaytiruvchi va bronxospazmni bartaraf qiluvchi dorilarni o‘z ichiga oladi: inhalyatsion kortikosteroidlar, bronxodilatorlar, leukotrien retseptor antagonistlari va biotexnologik preparatlar. Davolash bemorning simptomlari va kasallik faoliyatiga qarab moslashtiriladi.
Shunday qilib, bronxial astma kasalligini chuqur o‘rganish, uning patogenezi va klinik belgilarini aniqlash, zamonaviy diagnostika va individual davolash usullarini qo‘llash kasallik asoratlarini kamaytirish va bemorlarning hayot sifatini yaxshilashda hal qiluvchi ahamiyatga ega.
References
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention 2025 Update. Geneva: GINA; 2025.
Holgate, S. T., et al. The Pathophysiology of Asthma. The Lancet, 2015; 386: 156–166.
Barnes, P. J. Immunology of Asthma and Chronic Obstructive Pulmonary Disease. Nature Reviews Immunology, 2008; 8: 183–192.
Busse, W., & Lemanske, R. F. Asthma. New England Journal of Medicine, 2001; 344: 350–362.
Moffatt, M. F., et al. Genetic Variants Regulating ORMDL3 Expression Contribute to the Risk of Childhood Asthma. Nature, 2007; 448: 470–473.
Bousquet, J., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2016 Revision. Allergy, 2016; 71: 849–864.
Pavord, I. D., et al. Management of Severe Asthma: A European Respiratory Society/American Thoracic Society Guideline. European Respiratory Journal, 2014; 43: 343–373.
Wenzel, S. E. Asthma Phenotypes: The Evolution from Clinical to Molecular Approaches. Nature Medicine, 2012; 18: 716–725.
Chung, K. F., et al. International ERS/ATS Guidelines on Definition, Evaluation, and Treatment of Severe Asthma. European Respiratory Journal, 2014; 43: 343–373
Holgate, S. T. Pathogenesis of Asthma. Clinical & Experimental Allergy, 2008; 38: 872–897
Martinez, F. D., & Vercelli, D. Asthma. The Lancet, 2013; 382: 1360–1372.
National Heart, Lung, and Blood Institute (NHLBI). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NHLBI; 2007.
